3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
3
Phase 3
1
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Tumor-Agnostic
1
Conditions
Parasomnias
2
Lung Neoplasms
2
Weight Loss
1
Uveal Melanoma
1
Tuberous Sclerosis
1
Squamous Cell Carcinoma of Head and Neck
1
Smith-Magenis Syndrome
1
Sleep Wake Disorders
1
Neoplasms
1
Gastrointestinal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Cachexia
1
Breast Cancer - Female
1
Barrett Esophagus
1
Autism Spectrum Disorder
1
Anorexia
1
Angelman Syndrome
1
Interventions
Paclitaxel
20
Gemcitabine
16
Dexamethasone
16
Bevacizumab
16
Docetaxel
15
Oxaliplatin
14
Cyclophosphamide
13
Carboplatin
12
Capecitabine
12
Sorafenib
11
Fluorouracil
11
Leucovorin
10
Cisplatin
10
pembrolizumab
9
Pemetrexed
9
Epoetin Alfa
9
venetoclax
8
Prednisone
8
Fentanyl
8
Drug Therapy
8
Doxorubicin
8
atezolizumab
7
Rivaroxaban
7
Rituximab
7
Darbepoetin alfa
7
Anastrozole
7
Panitumumab
6
Ondansetron
6
Morphine
6
Irinotecan
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Neoplasms
×
Melatonin
×
Clear all
NCT02454855
2022-06-13
MEQAPAG
Centre Jean Perrin
Phase 3
Terminated
123 enrolled